Invention Grant
- Patent Title: NTRK2 fusions
-
Application No.: US14909040Application Date: 2014-07-30
-
Publication No.: US10407509B2Publication Date: 2019-09-10
- Inventor: Nicolas Stransky , Ethan G. Cerami , Christoph Lengauer
- Applicant: Blueprint Medicines Corporation
- Applicant Address: US MA Cambridge
- Assignee: Blueprint Medicines Corporation
- Current Assignee: Blueprint Medicines Corporation
- Current Assignee Address: US MA Cambridge
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
- International Application: PCT/US2014/048881 WO 20140730
- International Announcement: WO2015/017533 WO 20150205
- Main IPC: C07K16/40
- IPC: C07K16/40 ; C12Q1/6886 ; C12Q1/48 ; G01N33/574 ; C07K16/28 ; C07K16/30 ; C12N15/113
Abstract:
The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK, fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with NTRK fusions, such as conditions mediated by aberrant NTRK expression or activity, or overexpression of NTRK.
Public/Granted literature
- US20160272725A1 NTRK2 FUSIONS Public/Granted day:2016-09-22
Information query
